Core Insights - Pfizer reported adjusted EPS of $0.87, exceeding the consensus estimate of $0.64, and revenue of $16.65 billion, slightly above the expected $16.50 billion, leading to a 12.6% increase in pre-market trading [1][6] Financial Performance - Net income decreased by 20.84% year over year to $3.54 billion, while reported revenue fell by 5.92% from $17.70 billion in Q3 2024 [2][6] - Non-COVID revenue grew operationally by 4%, driven by strong performances in key franchises [3][6] Key Product Performance - Eliquis, an anticoagulant, saw a significant operational growth of 22%, while Vyndaqel for cardiac amyloidosis increased by 7% [3][7] - Conversely, Paxlovid revenue declined by 55% operationally, and Comirnaty vaccine revenue fell by 20% [3] Guidance and Strategic Moves - Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and raised EPS guidance to $3.00 to $3.15 from previous estimates, indicating confidence in execution and cost discipline [4][6] - CEO Albert Bourla mentioned a landmark agreement with the U.S. Government, which provides clarity for the business and alleviates investor concerns [4] - Recent strategic actions, including the proposed Metsepa acquisition, aim to enhance opportunities in high-growth markets, particularly in obesity treatment [5]